Author:
Giannotta Juri Alessandro,Fattizzo Bruno,Barcellini Wilma
Abstract
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by intravascular hemolytic anemia and thrombosis and is notoriously associated with aplastic anemia and myelodysplastic syndromes. Rarer associations include myeloproliferative neoplasms (MPNs), which are also burdened by increased thrombotic tendency. The therapeutic management of this rare combination has not been defined so far. Here, we describe a 62-year-old man who developed a highly hemolytic PNH more than 10 years after the diagnosis of MPN. The patient started eculizumab, obtaining good control of intravascular hemolysis but without amelioration of transfusion-dependent anemia. Moreover, we performed a review of the literature regarding the clinical and pathogenetic significance of the association of PNH and MPN. The prevalence of PNH clones in MPN patients is about 10%, mostly in association with JAK2V617F-positive myelofibrosis. Thrombotic events were a common clinical presentation (35% of subjects), sometimes refractory to combined treatment with cytoreductive agents, anticoagulants, and complement inhibitors. The latter showed only partial effectiveness in controlling hemolytic anemia and, due to the paucity of data, should be taken in consideration after a careful risk/benefit evaluation in this peculiar setting.
Reference63 articles.
1. Paroxysmal Nocturnal Hemoglobinuria;Brodsky;Blood,2014
2. Update on the Diagnosis and Management of Paroxysmal Nocturnal Hemoglobinuria;Parker;Hematol Am Soc Hematol Educ Program,2016
3. Thrombosis in Paroxysmal Nocturnal Hemoglobinuria;Hill;Blood,2013
4. How I Treat Paroxysmal Nocturnal Hemoglobinuria;Brodsky;Blood,2021
5. Flow Cytometric Diagnosis of Paroxysmal Nocturnal Hemoglobinuria: Pearls and Pitfalls - A Critical Review Article;Brando;EJIFCC,2019